Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing

Abstract

1. Findings support use of PB samples for chronic myeloid neoplasms and for acute leukemias with sufficient circulating disease.

2. In acute leukemias, BM appears to be superior to PB for monitoring measurable residual disease, even in the absence of BM excess blasts.